← All trials
NCT04771780
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2021
- Primary completion
- Jun 27, 2022
- Completion date
- Jun 27, 2022
- First posted
- Feb 25, 2021
- Last posted
- Sep 8, 2021
- Enrollment
- 213
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kyowa Hakko KirinLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.